Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.

Nature communications - 11 May 2020

Ge Jennifer Y, Shu Shaokun, Kwon Mijung, Jovanović Bojana, Murphy Katherine, Gulvady Anushree, Fassl Anne, Trinh Anne, Kuang Yanan, Heavey Grace A, Luoma Adrienne, Paweletz Cloud, Thorner Aaron R, Wucherpfennig Kai W, Qi Jun, Brown Myles, Sicinski Piotr, McDonald Thomas O, Pellman David, Michor Franziska, Polyak Kornelia

Abstract excerpt

BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxel, a microtubule inhibitor, synergize with the BET inhibitor JQ1 in TNBC lines. High-complexity DNA barcoding and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azepines
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Paclitaxel

Share to Retinoblastoma Protein

Share to Triazoles

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32393766
DOI: 10.1038/s41467-020-16170-3
PMCID: PMC7214447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.PMID 32393766Read ↗

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional MachinerySemantic proximity Read ↗

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity Read ↗

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read ↗

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsSemantic proximity Read ↗

Genome Instability and Pressure on Non-Homologous end Joining drives Chemotherapy Resistance via a DNA Repair Crisis Switch in Triple Negative Breast Cancer.Semantic proximity Read ↗

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysSemantic proximity Read ↗

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancerSemantic proximity Read ↗

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.Semantic proximity Read ↗

Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancerSemantic proximity Read ↗

Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancersSemantic proximity Read ↗

Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancerSemantic proximity Read ↗

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.